In this podcast, Dr. Patrice Hugo, Chief Scientific Advisor at IQVIA Laboratories discusses the selection and use of biomarkers in Immuno-oncology trials and the importance of early engagement between sponsors and clinical trial partners.
Too often, in early phase clinical trials, drug developers for immuno-oncology investigation of products are considering biomarkers as true CDx or companion diagnostics; when in fact, they aim at producing information at a later stage, evaluating the potential of these bio-markers to be of CDx. At times this adds pressure to the clinical labs to validate the assays to a level of stringency that is not necessarily required at that early stage. It also adds to the cost and complexity of the study. For bio-markers not considered as companion diagnostics, one of the main problems is how the data is generated, and how it's going to be used by the sponsor to support their drug development. Dr. Hugo explains the importance of the results generated from candidate companion diagnostic markers, the relationship with IVD manufacturers that are developing CDx and the global regulatory environmen
Related Insights
The End to End Importance of Selecting the Right Biomarker in Cancer Studies
A critical component in the fight against cancer and optimizing treatment outcomes for patients
IQVIA Laboratories Biomarker Services
Providing tools and experience to maximize your biomarker strategy
Biomarker roadmap to success
Develop a biomarker roadmap for a successful strategy in developing targeted therapies
Building a Best-in-Class Model for Global CDx Clinical Trial Deployment
11th Annual World Clinical Biomarkers & CDx Summit
Translational Science and Innovation Laboratory (TSAIL)
Translational biomarker solutions to accelerate the adoption of assays into clinical trials though new technology evaluation and early biomarker discovery
Alzheimer’s Disease Clinical Trials
Innovative laboratory solutions to accelerate progress
Biomarker-Driven Trials: How Laboratory Insight Can Enhance Clinical Trial Design and Optimize Drug Development
Diabetes Solutions
Learn how we support our customers across the development continuum in their fight against the global diabetes epidemic.
Next Generation Immuno-Oncology Flow Cytometry with Mark Edinger
I-O clinical development podcast series
A Pan-Cancer view of gene expression in Immuno-Oncology with particular applications in ovarian cancer
Advantages of RNA-Seq for measurement of immune response
